Online citations, reference lists, and bibliographies.

FDG PET/CT: EANM Procedure Guidelines For Tumour Imaging: Version 2.0

Ronald Boellaard, Roberto C. Delgado-Bolton, Wim J. G. Oyen, Francesco Giammarile, Klaus Tatsch, Wolfgang Eschner, Fred J. Verzijlbergen, Sally F Barrington, Lucy C Pike, Wolfgang Andreas Weber, Sigrid Stroobants, Dominique Delbeke, Kevin J. Donohoe, Scott Holbrook, Michael M. Graham, Giorgio Testanera, Otto S. Hoekstra, Josée M Zijlstra, Eric P. Visser, Corneline J. Hoekstra, Jan Pruim, Antoon T. M. Willemsen, Bertjan Arends, Jörg Kotzerke, Andreas Bockisch, Thomas Beyer, Arturo Chiti, Bernd J. Krause
Published 2014 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET is a quantitative imaging technique and therefore requires a common quality control (QC)/quality assurance (QA) procedure to maintain the accuracy and precision of quantitation. Repeatability and reproducibility are two essential requirements for any quantitative measurement and/or imaging biomarker. Repeatability relates to the uncertainty in obtaining the same result in the same patient when he or she is examined more than once on the same system. However, imaging biomarkers should also have adequate reproducibility, i.e. the ability to yield the same result in the same patient when that patient is examined on different systems and at different imaging sites. Adequate repeatability and reproducibility are essential for the clinical management of patients and the use of FDG PET/CT within multicentre trials. A common standardised imaging procedure will help promote the appropriate use of FDG PET/CT imaging and increase the value of publications and, therefore, their contribution to evidence-based medicine. Moreover, consistency in numerical values between platforms and institutes that acquire the data will potentially enhance the role of semiquantitative and quantitative image interpretation. Precision and accuracy are additionally important as FDG PET/CT is used to evaluate tumour response as well as for diagnosis, prognosis and staging. Therefore both the previous and these new guidelines specifically aim to achieve standardised uptake value harmonisation in multicentre settings.
This paper references
Where are we now? Summary report of the second international workshop on PET/MR imaging
Dl Bailey (2013)
10.1007/s11307-009-0207-2
A Randomised Controlled Trial Assessing the Effect of Oral Diazepam on 18F-FDG Uptake in the Neck and Upper Chest Region
Marieke G. G. Sturkenboom (2009)
10.1007/s00261-005-0380-y
ESUR guidelines on contrast media
Henrik S. Thomsen (2005)
German guideline
Bj Krause (2007)
Predictive and prognostic value of FDG - PET in nonsmall - cell lung
LF Geus-Oei
Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.
Ronald Boellaard (2004)
10.3413/nukmed-282
FDG-PET/CT in der Onkologie
Bernd Joachim Krause (2007)
10.1183/09031936.01.17408020
The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.
Johan F Vansteenkiste (2001)
10.1200/JCO.2013.53.5229
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
Sally F Barrington (2014)
10.1016/j.jacr.2006.10.011
FDG-PET CT for tumor imaging.
Janet C. Miller (2007)
10.1111/j.1467-3010.1977.tb00966.x
Research on obesity.
W. Philip T. James (1977)
Use of PET for monitoring cancer therapy and for predicting outcome.
Wolfgang Andreas Weber (2005)
10.1016/j.jacr.2005.03.014
Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance.
Robert Coleman (2005)
Understanding the standardized uptake value, its methods, and implications for usage.
J. A. Thie (2004)
18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
Steven M. Larson (2006)
10.3109/10428194.2015.1029748
Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19–20 September 2014
Michel Meignan (2015)
10.1007/s00259-008-0874-2
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
Ronald Boellaard (2008)
Quantitative Imaging Biomarkers Alliance. Quantitative FDG-PET Technical Committee. UPICT oncology FDG-PET CT protocol. http://qibawiki.rsna.org/index.php?title=FDG-PET_tech_ctte
(2014)
10.1007/s00330-012-2478-2
Suppression of myocardial 18F-FDG uptake with a preparatory “Atkins-style” low-carbohydrate diet
Richard Coulden (2012)
10.1177/0193945910394380
Systematic Review
Fatemeh Heshmati Nabavi (2012)
Pattern of uptake and excretion of (18)F-FDG in the lactating breast.
Rodney J. Hicks (2001)
10.1007/s00259-014-2731-9
Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines
Michael Lassmann (2014)
on Drugs and Contrast Media
ACR Committe (2013)
10.1097/RLU.0b013e318251e3d1
Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With 18F-FDG PET/CT in Non–Small Cell Lung Cancer
Charline Lasnon (2012)
10.1097/MNM.0b013e328155d154
A novel iterative method for lesion delineation and volumetric quantification with FDG PET
Jorn A. van Dalen (2007)
10.3109/10428194.2013.802784
Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012
Michel Meignan (2014)
10.1007/s00259-006-0131-5
How should we analyse FDG PET studies for monitoring tumour response?
Adriaan A. Lammertsma (2006)
10.1016/S1095-0397(01)00062-0
Reduction of myocardial 2-deoxy-2-[18F]fluoro-D-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction.
Darren P Lum (2002)
10.1007/BF03027388
The effect of oral contrast on large bowel activity in FDG-PET/CT
Hideki Otsuka (2005)
10.2967/jnumed.110.075689
Molecular Imaging in Radiotherapy Planning for Head and Neck Tumors
Vincent Grégoire (2011)
and Standards Committee
ACR Guideline (2014)
Research on obesity. London: Her Majesty's Stationery Office
W James (1976)
10.1007/s00259-009-1264-0
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2
Andrea Varrone (2009)
10.1097/MNM.0b013e3282eff2d5
FDG PET in lymphoma: The need for standardization of interpretation. An observer variation study
Josée M Zijlstra (2007)
10.1148/66.1.110i
Society of Nuclear Medicine
Clifford Goodman (1988)
Intravenous administration of diazepam significantly reduces brown fat activity on 18F-FDG PET/CT.
Rajan Rakheja (2011)
Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis
HH Chung (2015)
10.1007/s00259-006-0318-9
Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol
Veli Söderlund (2006)
New EANM FDG PET/CT accreditation specifications for SUV recovery coefficients
Eanm Research Ltd
Acquisition protocol considerations for combined PET/CT imaging.
Thomas Beyer (2004)
10.1016/S0001-2998(96)80006-7
Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.
Gary J. R. Cook (1996)
Protocol for establishing and maintaining the calibration of medical radionuclide calibrators and their quality control.
Robyn Gadd (2006)
10.1016/j.acra.2012.07.002
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Hao Zhang (2013)
10.1200/JCO.2006.08.2305
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
Malik E Juweid (2007)
10.1038/sj.bjc.6601088
Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002)
Patrick Bourguet (2003)
Measurement of 18F-FDG concentrations in blood samples: comparison of direct calibration and standard solution methods.
Henri N.J.M. Greuter (2003)
Society of Nuclear Medicine. The SNM procedure guideline for general imaging 6
10.1016/S0009-9260(80)80176-0
The royal college of radiologists.
Robert E. Steiner (1975)
10.1007/s00259-008-0826-x
Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology
Jan Stauss (2008)
10.1007/s00259-006-0363-4
A gradient-based method for segmenting FDG-PET images: methodology and validation
Xavier Geets (2006)
10.1007/s00259-009-1224-8
Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma
Felisa Jiménez-Requena (2009)
Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors.
Roberto C. Delgado-Bolton (2003)
The Royal College of Radiologists. Standards for radiology discrepancy meetings. London: The Royal College of Radiologists
(2007)
10.1007/s00259-013-2435-6
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
Emmanuel Itti (2013)
Standards for radiology discrepancy meetings. London: The Royal College of Radiologists
Society of Nuclear Medicine. The SNM procedure guideline for general imaging 6.0
10.1016/j.rcl.2004.09.006
Monitoring response to treatment in patients utilizing PET.
Norbert E Avril (2005)
10.1088/0031-9155/52/12/010
Fuzzy hidden Markov chains segmentation for volume determination and quantitation in PET.
Mathieu Hatt (2007)
10.1016/S0969-8051(00)00155-4
Anatomy of SUV
Sung-Cheng Huang (2000)
18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited wholebody technique
MM Osman (2010)
10.1200/JCO.2005.01.1189
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Corneline J. Hoekstra (2005)
10.1007/s00259-008-0875-1
A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data
Andrea Schaefer (2008)
Department of Radiology and Biomedical Imaging. Contrast administration in patients receiving metformin
San Francisco (2014)
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.
Dominique Delbeke (2006)
10.1080/10428190903040048
Report on the First International Workshop on interim-PET scan in lymphoma
Michel Meignan (2009)
10.1016/j.radonc.2010.07.009
PET/CT (and CT) instrumentation, image reconstruction and data transfer for radiotherapy planning.
Bernhard Sattler (2010)
10.1007/s00259-014-2817-4
Pediatric Radiopharmaceutical Administration: Harmonization of the 2007 EANM Paediatric Dosage Card (Version 1.5.2008) and the 2010 North American Consensus guideline
Michael Lassmann (2014)
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
Lalitha K. Shankar (2006)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H Young (1999)
Recommendations for cross-sectional imaging in cancer management, Second edition: Colon, rectum and anal canal cancer
Anwar Padhani (2006)
10.2967/jnumed.109.066399
PET and PET/CT Reports: Observations from the National Oncologic PET Registry
Robert E. Coleman (2010)
Cumulative index to the annual catalogues of Her Majesty's Stationery Office publications, 1922-1972
Ruth Matteson Blackmore (1976)
FDG-PET/CT in oncology
BJ Krause (2007)
10.2967/jnumed.113.136986
Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging
Abdel Kader Tahari (2014)
10.2174/157340506776930601
A Systematic Review of the Efficacy of 18F-FDG PET in Unknown Primary Tumors
Roberto C. Delgado-Bolton (2006)
10.1007/s00259-009-1297-4
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
Ronald Boellaard (2009)
Report on the 4 th International Workshop on Positron Emission Tomography in Lymphoma held in Menton , France , 3 - 5 October
M Meignan (2012)
10.2967/jnumed.112.112524
EANM/SNMMI Guideline for 18F-FDG Use in Inflammation and Infection*
François Jamar (2013)
dose to patients from radiopharmaceuticals
ICRP. Radiatio (2007)
ACR-SPR practice parameter for performing FDG-PET/CT in oncology
Acr Guidelines (2014)
University of California San Francisco. Department of Radiology and Biomedical Imaging. Contrast administration in patients receiving metformin
10.1097/MNM.0b013e32835d1034
Proposal for an optimized protocol for intravenous administration of insulin in diabetic patients undergoing 18F-FDG PET/CT
Federico Caobelli (2013)
10.1007/s11307-013-0623-1
Summary Report of the First International Workshop on PET/MR Imaging, March 19–23, 2012, Tübingen, Germany
Dale L Bailey (2013)
10.1007/s11604-012-0076-5
The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients
Joji Kawabe (2012)
EANM procedure guidelines for tumour PET imaging: version 1.0
R Boellaard (2010)
10.1007/s12149-007-0012-4
FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues
Ryogo Minamimoto (2007)
10.2967/jnumed.110.077255
Repeatability of Metabolically Active Volume Measurements with 18F-FDG and 18F-FLT PET in Non–Small Cell Lung Cancer
Virginie Frings (2010)
10.1007/s11307-014-0725-4
Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8–12, 2013, Tubingen, Germany
Dale L Bailey (2014)
10.1148/radiol.2303021287
Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation.
Gerald Antoch (2004)
[FDG-PET/CT in oncology. German Guideline].
Bernd J. Krause (2007)
10.1007/s00259-004-1566-1
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial
Nanda C. Krak (2004)
10.1245/s10434-011-2153-x
Prognostic Value of Preoperative Metabolic Tumor Volume and Total Lesion Glycolysis in Patients with Epithelial Ovarian Cancer
Hyun Hoon Chung (2011)
10.1016/j.ejca.2005.03.026
Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer.
Gerben R. Borst (2005)
10.1016/j.radonc.2010.07.015
PET in radiotherapy planning: particularly exquisite test or pending and experimental tool?
Vincent Grégoire (2010)
Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in
10.3413/Nukmed-0452-11-12
Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy planning of lung cancer.
Annika Schäfer (2012)
10.1007/s00259-013-2391-1
Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients
Charline Lasnon (2013)
Imaging in the evaluation of cancer
AR Padhani (2014)
10.2967/jnumed.109.071878
Absorbed 18F-FDG Dose to the Fetus During Early Pregnancy
Paolo Zanotti-Fregonara (2010)
10.1016/j.ijrobp.2006.03.015
Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers.
Regiane S Andrade (2006)
10.1148/radiol.14132807
Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study.
Virginie Frings (2014)
EARL procedure for assessing PET/CTsystem specific patient FDG activity preparations for quantitative FDG PET/CT studies
R Boellaard (2014)
10.2214/AJR.04.1740
Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation.
Osama R. Mawlawi (2006)
10.2967/jnumed.108.057182
Standards for PET Image Acquisition and Quantitative Data Analysis
Ronald Boellaard (2009)
FDG-PET/CT as an imaging biomarker measuring response to cancer therapy, version 1.05, Publicly Reviewed Version
Quantitative Imaging (2013)
Imaging in the evaluation of cancer In: Nicholson T, editor. Recommendations for cross-sectional imaging in cancer management The Royal College of Radiologists
Ar Padhani (2014)
10.3949/ccjm.74.5.361
Intravenous iodinated contrast agents: risks and problematic situations.
Kimmie L. Bui (2007)
Eur J Nucl Med Mol Imaging (2009) 36:1167–1175 DOI 10.1007/s00259-009-1076-2 ORIGINAL ARTICLE
10.1002/cncr.22979
Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review.
Lioe-Fee de Geus-Oei (2007)
10.1007/s00259-007-0456-8
Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary
Pavel Fencl (2007)
ACR-SPR practice parameter for performing FDG-PET/CT in oncology. American College of Radiology
Acr Guidelines
10.2967/jnumed.108.057307
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl (2009)
10.1016/j.radonc.2010.07.021
Clinical use of PET-CT data for radiotherapy planning: what are we looking for?
Arturo Chiti (2010)
10.2967/jnumed.107.047787
Recommendations on the Use of 18F-FDG PET in Oncology
James W. Fletcher (2008)
10.3413/Nukmed-0455-11-12
Integration of FDG-PET/CT into external beam radiation therapy planning: technical aspects and recommendations on methodological approaches.
Daniela Thorwarth (2012)
10.2214/AJR.09.3731
18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique.
Medhat M. Osman (2010)
10.2174/1573405610703010003
The Use of PET for Radiotherapy
Yusuf E. Erdi (2007)
FDG-PET/CT as an imaging biomarker measuring response to cancer therapy, version 1.05, Publicly Reviewed Version. Quantitative Imaging Biomarkers Alliance
10.2967/jnumed.112.112177
Reporting Guidance for Oncologic 18F-FDG PET/CT Imaging
Ryan D. Niederkohr (2013)
10.2967/jnumed.108.060590
Comparison of Imaging Protocols for 18F-FDG PET/CT in Overweight Patients: Optimizing Scan Duration Versus Administered Dose
Yoko Masuda (2009)
10.2967/jnumed.110.083865
Quantifying and Reducing the Effect of Calibration Error on Variability of PET/CT Standardized Uptake Value Measurements
Catherine Marie Lockhart (2011)
10.1016/j.ctrv.2003.07.004
The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Esther Bastiaannet (2004)
18F]FDG-PET scan in patients with fasting hyperglycaemia
O Belohlavek (2014)
10.2165/00003088-200544100-00004
Quantification of Lean Bodyweight
Sarayut Janmahasatian (2005)
10.1007/978-3-642-03902-7_134
Radiation dose to patients from radiopharmaceuticals
Sören Mattsson (2009)
10.1259/bjr/26964464
Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines.
Henrik S. Thomsen (2003)
10.1016/s0098-1672(08)79209-9
Recommendations on the Use of 18F-FDG PET in Oncology
Allen D. Elster (2009)
10.1016/j.icrp.2008.08.003
Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007.
Icrp (2008)
10.1186/2191-219X-3-63
Optimized dose regimen for whole-body FDG-PET imaging
Eleonore H de Groot (2013)
10.2967/jnumed.112.108530
Reference Range for Intrapatient Variability in Blood-Pool and Liver SUV for 18F-FDG PET
Raef R. Boktor (2013)
10.1111/j.1365-2125.1981.tb01163.x
Should clearance be normalised to body surface or to lean body mass?
T H Hallynck (1981)
10.1007/s00259-006-0224-1
Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters
Marinke Westerterp (2006)
Anatomy of SUV. Standardized uptake value.
S. C. Huang (2000)
CT of patients with cancer: comparison of whole-body and limited wholebody technique
Mm Osman (2010)
10.2967/jnumed.114.139980
International Guidelines for Pediatric Radiopharmaceutical Administered Activities
S. T. Treves (2014)
Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine.
Heinrich R. Schelbert (1998)
10.1016/j.cccn.2004.06.010
Accuracy of the EasyTouch blood glucose self-monitoring system: a study of 516 cases.
Ken-Shwo Dai (2004)
10.1007/s00259-011-1899-5
Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology
Patsuree Cheebsumon (2011)
10.1007/s00259-009-1348-x
Acceptance testing for nuclear medicine instrumentation
Ellinor Busemann Sokole (2009)



This paper is referenced by
10.1007/s12350-020-02200-6
Rubidium-82 generator yield and efficiency for PET perfusion imaging: Comparison of two clinical systems
Ali Ahmadi (2020)
10.1088/2057-1976/ab6996
Improved PET quantification and harmonization by adaptive denoising
Mauro Namías (2020)
10.1016/J.LUNGCAN.2019.03.013
Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence.
V Grøndahl (2019)
10.2967/jnmt.118.211474
Validation of the Semiautomatic Quantification of 18F-Fluoride PET/CT Whole-Body Skeletal Tumor Burden
Ana Emília Teixeira Brito (2018)
10.2967/jnmt.118.213405
Protocols for Harmonized Quantification and Noise Reduction in Low-Dose Oncologic 18F-FDG PET/CT Imaging
Marcos Aurélio Machado (2019)
A protocol for systematic review and meta analysis
Dongchun Xuan (2020)
10.1016/J.MEDCLE.2018.08.003
Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus 18FDG positron emission tomography/computed tomography in initial staging and restaging after treatment
Nieves Gómez León (2018)
10.1016/j.acra.2019.04.016
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Mengmeng Jiang (2019)
10.1186/s13550-019-0569-7
SUV variability in EARL-accredited conventional and digital PET
Daniëlle Koopman (2019)
10.1007/s12149-018-1318-0
Clinical evaluation of CT radiation dose in whole-body 18F-FDG PET/CT in relation to scout imaging direction and arm position
Yusuke Inoue (2018)
10.1155/2019/7954854
Nuclear Imaging of Glucose Metabolism: Beyond 18F-FDG
Han Feng (2019)
10.1007/s12149-016-1135-2
Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction
Charline Lasnon (2016)
10.1016/j.rx.2016.12.001
PET-CT in presurgical lymph node staging in non-small cell lung cancer: the importance of false-negative and false-positive findings.
Ana García de Castro (2017)
EANM / EANO / RANO practice guidelines / SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ F-18 ] FDG
Ian Law (2019)
Microparticules à base d’amidon (SBMP) comme agent théranostique unique pour la radiothérapie sélective interne des tumeurs hépatiques : radiomarquage au gallium-68 et rhénium-188 et étude préliminaire in vivo
Elise Verger (2016)
10.3990/1.9789036541947
Biomarkers for the early detection of cancer treatment induced cardiotoxicity
Bernard Frederik Bulten (2016)
10.1007/s12350-015-0124-5
Debate: Molecular cardiac imaging is ready for the prime time con between wishful thinking and reality
Ignasi Carrió (2015)
10.1186/s13550-016-0228-1
The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients
Evan C Frary (2016)
10.1007/s12350-017-1063-0
Role of 18F-FDG PET/CT in the diagnosis of cardiovascular implantable electronic device infections: A meta-analysis
Maryam Bakir Mahmood (2017)
10.1007/s00259-017-3913-z
Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse
Roberto C Delgado Bolton (2017)
10.1007/s13246-017-0596-5
Optimization of a shorter variable-acquisition time for legs to achieve true whole-body PET/CT images
Takuro Umeda (2017)
10.1016/J.NIMA.2017.04.035
Application of EARL (ResEARch 4 Life®) protocols for [18F]FDG-PET/CT clinical and research studies. A roadmap towards exact recovery coefficient
Marcin Balcerzyk (2017)
10.4254/wjh.v9.i11.562
18-Fluoro-deoxyglucose uptake in inflammatory hepatic adenoma: A case report
Willy Liu (2017)
10.3892/ijo.2020.4955
PET/CT and PET/MRI in ophthalmic oncology (Review)
M. Kalemaki (2020)
10.1002/mp.12311
Validation of phantom‐based harmonization for patient harmonization
Joseph V. Panetta (2017)
10.1007/s12149-015-1041-z
Current generation time-of-flight 18F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands
Daniëlle Koopman (2015)
10.1148/radiol.2018171756
Rapid Contour-based Segmentation for 18F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation.
Florent L. Besson (2018)
10.1186/s13550-018-0461-x
Optimization of a dedicated protocol using a small-voxel PSF reconstruction for head-and-neck 18FDG PET/CT imaging in differentiated thyroid cancer
Renaud Ciappuccini (2018)
The Effectiveness of Hyoscine-N-Butylbromide ( Buscopan ) in Reducing Physiological Bowel Uptake in 18 F-FDG PET / CT
Mohd Ramli (2018)
10.31661/jbpe.v0i0.792
Personalized 18FDG Dose Synthesis Using BG-75 Generator: 1st Year Experience at JCI Accredited Tertiary Care Hospital in Pakistan
Zaman M U. (2019)
Intérêt diagnostique de la tomographie par émission de positons au 18 F-FDG, couplée à la tomodensitométrie dans l’endocardite infectieuse sur valve native
Carole Chaban (2017)
10.1007/s12350-017-1121-7
18F-FDG PET/CT for the quantification of inflammation in large carotid artery plaques
Kjersti Johnsrud (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar